Hammerstone Pro Trader

This Powerful Solution Allows You To Communicate & Collaborate In Real-Time Alongside Our Pro Data Stream

What Is Hammerstone Pro Trader?

All our monthly plans come with a 14-day free trial and no fixed contract.

Hammerstone Pro Feed

The Hammerstone Pro Feed is our most powerful solution and a trusted resource that has been providing Wall Street with data since 2001. Using either Bloomberg’s IB manager, Symphony and other platforms, the Pro feed allows you to communicate and collaborate with other Pro traders in real-time to discuss intra-day news, markets and securities. The chat window allows you to see the news and chat stream simultaneously, providing you with the same tools as real Wall Street traders.

START A 14 DAY FREE TRIAL

Hammerstone Reports

Hammerstone Reports are expertly written daily updates sent 4 times per day directly to your inbox. These reports give you an in-depth analysis of earnings reports, street recommendations, economic data, sector news, market movers and more. Here are examples of the reports:

START A 14 DAY FREE TRIAL

Get Started With Hammerstone Pro For Free

Hammerstone Reports

4x Daily Reports

$49/mo
 

Start Your Free 14 Day Trial

  • Up-To-Date Reports (4x Daily)
  • News & In-Depth Analysis
  • Early Look Edition
  • Mid Morning Look Edition
  • Street Recommendations Edition
  • Daily Recap Edition
  • Delivery via Email
  • 14-Day Free Trial
  • Cancel Anytime

Start Your Free 14 Day Trial

Hammerstone Pro Trader

Get the Pro feed only

$299/mo
* Discounts Available For Multiple Licenses

Start Your Free 14 Day Trial

  • Strictly For The Professional Trader
  • Pro Trader Data Feed
  • Real Time Chat Alongside Data Feed
  • Pro Members Vetted To Maintain Chat Room Integrity
  • Filter functionality in data feed
  • Hammerstone 4x Daily Reports
  • Real-Time Breaking News With Context
  • Proprietary Research
  • Delivery via Web/Bloomberg/Symphony
  • Desktop & Mobile Compatible
  • 14-Day Free Trial
  • Cancel Anytime

Start Your Free 14 Day Trial

COMPLETE PRO TRADER PACKAGE

Pro Trader Data Feed + 4X Daily Reports

$349/mo
* Discounts Available For Multiple Licenses

Start Your Free 14 Day Trial

  • All Features of Pro Data Feed & Reports
  • Real Time Chat Alongside Data Feed
  • Pro Members Vetted To Maintain Chat Room Integrity
  • Real-Time Breaking News With Context
  • Actionable Ideas, Running Commentary
  • Earnings Releases & Interpretation
  • Proprietary Research & Index Levels
  • Delivery via Web App (No Install Required)
  • 4x Daily Editions Of Hammerstone Reports
  • Desktop & Mobile Compatible
  • 14-Day Free Trial
  • Cancel Anytime

Start Your Free 14 Day Trial

No obligations, no contracts, cancel at any time, 100% risk free.

Here's Yesterday's Market Pro Sample Feed

Please Note: This Is A Delayed Example (without the Chat Room), Not The Live Feed.

  • Posted At:2019-01-14T12:35:27Z

    PPG @ CSFB - Given weaker auto data, a choppy macro and skepticism re: housing (in both Euro / US), we believe expectations are fairly low heading into the 4Q print It is our view PPG had some 4Q raw material relief, giving latitude on margins / EPS. After adjusting for weaker auto, vulnerable China data, lower raw materials, multiple new acquisitions and FX, our '18 / '19 EPS go to $5.80 /$6.75, respectively Forward commentary will be crucial to performance given the bulls' euphoria re: raw deflation vs the bear's focus on weaker end markets We remain comfortably on the sidelines given macro uncertainty, as well as our belief raw deflation will be a modest tailwind for the time being It's worth stressing that deteriorating energy demand is likely a direct function of a weakening macro, so we argue "you can't have your cake and eat it too". PPG @ CSFB

  • Posted At:2019-01-14T12:35:27Z

    MNST @ DB - Last Friday, we hosted a bull/bear debate on MNST with 22 investors in New York City (please click here for an accompanying slide deck, which includes proprietary findings from a recent dbDIG survey of US beverage consumers) Investor sentiment was decidedly split, though bulls were more vocal and exhibited more conviction at current levels, while bears seemed to be lying in wait for the next leg up Key topics at the debate centered around Bang, the KO relationship, potential impacts from MNST 's recent pricing in the US, MNST 's international opportunity, and what investors expect to hear from MNST at their upcoming investor meeting on January 17th Last Close USD54.37, Buy MNST @ DB

  • Posted At:2019-01-14T12:35:18Z

    *VW SAYS NEEDS TO BE SMART WITH INVENTORY IN SLOWING CAR MARKET

  • Posted At:2019-01-14T12:34:19Z

    Maxar Technologies Announces CEO TransitionCanada NewsWireWESTMINSTER, Colo., Jan 14, 2019 Daniel Jablonsky, President of DigitalGlobe, named as CEO. WESTMINSTER, Colo., Jan 14, 2019 /CNW/ -- Maxar Technologies (NYSE:MAXR) (TSX:MAXR) ("Maxar" or the "Company"), a global technology innovator powering the new space economy, today announced the appointment of Daniel Jablonsky as President and Chief Executive Officer of Maxar, effective immediately Mr Jablonsky, who most recently served as President of DigitalGlobe, a Maxar Technologies company, will also join the Maxar Board of Directors He succeeds Howard Lance, who has resigned from his roles as President and Chief Executive Officer and as a Director of Maxar.

  • Posted At:2019-01-14T12:34:06Z

    *VW OF AMERICA CEO SCOTT KEOGH SPEAKS IN BLOOMBERG TV INTERVIEW

  • Posted At:2019-01-14T12:34:02Z

    *VW'S KEOGH SAYS SEDANS STILL SEGMENT WORTH PURSUING

  • Posted At:2019-01-14T12:33:58Z

    MSFT @ DB - Microsoft (MSFT ) - Security is a New Growth Engine Our First Look at Microsoft s Security Portfolio While Microsoft is considered best-of-breed in many markets, the prevailing Street narrative about its security suite is that it is good enough for a segment of the market but not particularly competitive against enterprise pure-plays such as Symantec, Proofpoint or Okta Yet during our field checks over the last few quarters, we heard a clear tone shift from customers and partners, with more flagging material investments by Microsoft in its security suite and real traction among enterprise customers This feedback prompted us to explore this angle of Microsoft , one that in our view is flying below the radar of most Street analysts and that is central to Microsoft s emerging ARPU growth story Last Close USD102.8, Buy MSFT @ DB

  • Posted At:2019-01-14T12:33:57Z

    *VW'S KEOGH SAYS GOOD TRANSPARENCY ON NAFTA, `IN GOOD SHAPE'

  • Posted At:2019-01-14T12:33:40Z

    NPTN

  • Posted At:2019-01-14T12:33:37Z

    *NEOPHOTONICS 4Q PRELIM ADJ EPS 0C-4C, EST. LOSS 3C

  • Posted At:2019-01-14T12:33:23Z

    DAL down 1.7% after BofAML d/g

  • Posted At:2019-01-14T12:32:39Z

    WDC down 5% after Evercore d/g

  • Posted At:2019-01-14T12:32:28Z

    MDB @ JMP - maintain our Market Perform rating on MongoDB after Amazon introduced a competitive product on January 9, 2019 called DocumentDB, which it describes as a "fast, scalable, and highly available document database that is designed to be compatible with your existing MongoDB applications and tools," causing MongoDB to trade down 14% over the next two days - MDB @ JMP

  • Posted At:2019-01-14T12:32:06Z

    Data Supporting the Cardiovascular Safety of VIVUS Qsymia Published in The Journal of Clinical Endocrinology & Metabolism Data Supporting the Cardiovascular Safety of VIVUS Qsymia Published in The Journal of Clinical Endocrinology & Metabolism -Study finds no increase in risk for major adverse cardiovascular events for individuals currently using phentermine in combination with topiramate; study adds to robust data supporting the safety and efficacy of Qsymia- CAMPBELL, Calif., Jan 14, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc (Nasdaq: VVUS; the Company ), a biopharmaceutical company, today announced that results from a new study evaluating the cardiovascular safety of Qsymia (phentermine and topiramate extended-release) capsules CIV will be published in the February 1, 2019 issue of The Journal of Clinical Endocrinology & Metabolism and are currently available online.1 This retrospective study, conducted using medical claims databases, was prompted by the observation in clinical trials that participants taking Qsymia had higher heart rates than those taking placebo The new findings indicate that the combined risk of major adverse cardiovascular events (MACE) was not elevated in patients currently taking Qsymia, or concurrently taking both phentermine and topiramate, compared with former users of these medications The number of MACE events (3 events during 3,245 person-years of follow-up) was too few to draw a definitive conclusion from the data Results from the study were previously presented in a poster at the 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management in August 2018.

  • Posted At:2019-01-14T12:31:56Z

    *NEOPHOTONICS SEES 4Q RESTRUCTURING CHARGES ABOUT $5.7M

Get Started With Hammerstone Pro For Free

Hammerstone Reports

4X Daily Reports

$49/mo
 

Start Your Free 14 Day Trial

Hammerstone Pro Trader

Get the Pro feed only

$299/mo
* Discounts Available For Multiple Licenses

Start Your Free 14 Day Trial

COMPLETE PRO TRADER PACKAGE

Pro Trader Data Feed + 4x Daily Reports

$349/mo
* Discounts Available For Multiple Licenses

Start Your Free 14 Day Trial

No obligations, no contracts, cancel at any time, 100% risk free.